Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares in the company, valued at approximately $88,176,020.54. The trade was a 1.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 1.5%

Shares of JAZZ stock opened at $247.72 on Wednesday. The company has a market capitalization of $15.56 billion, a P/E ratio of -12,379.81, a P/E/G ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $249.64. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The firm has a 50-day moving average price of $230.28 and a 200 day moving average price of $196.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.07 billion for the quarter. Research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on JAZZ. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Robert W. Baird set a $252.00 target price on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Bank of America lifted their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Finally, Raymond James Financial restated an “outperform” rating and issued a $239.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.94.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 18.8% in the second quarter. GAMMA Investing LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $339,000 after buying an additional 223 shares during the period. Harbor Investment Advisory LLC lifted its stake in shares of Jazz Pharmaceuticals by 349.2% in the 2nd quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 227 shares during the period. Versant Capital Management Inc boosted its position in shares of Jazz Pharmaceuticals by 14.9% in the 2nd quarter. Versant Capital Management Inc now owns 2,357 shares of the specialty pharmaceutical company’s stock worth $568,000 after purchasing an additional 305 shares during the last quarter. NewEdge Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 132.6% during the first quarter. NewEdge Advisors LLC now owns 1,975 shares of the specialty pharmaceutical company’s stock worth $373,000 after purchasing an additional 1,126 shares during the period. Finally, Glenmede Trust Co. NA grew its stake in shares of Jazz Pharmaceuticals by 1.9% during the first quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock worth $1,478,000 after purchasing an additional 146 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.